Anti-Hu EGFR (pY1173) Purified

Anti-Hu EGFR (pY1173) Purified
Regulatory status
RUO
Antigen
EGFR (pY1173)
Clone
EM-13
Format
Purified
Reactivity
Human
Application
FC, IP, WB
Variant
0.1 mg
11-575-C100
In stock

0.025 mg
11-575-C025
In stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
Images
References
Isotype
Mouse IgG1
Specificity
The antibody EM-13 reacts with human EGFR (ErbB1 / HER1) phosphorylated on tyrosine 1173.
Application
FC, IP, WB
Reactivity
Human
Immunogen
Synthetic phospho-peptide covering sequence around tyrosine 1173 of human EGFR.
Other names
EGFR, EGF R, Her1, ERBB1, PIG61, NISBD2
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.
11-575 WB
Western blotting analysis of EGFR (phospho-Tyr1173) by mouse monoclonal antibody EM-13 in EGF-treated A431 (A), CALU-3 (B), MCF-7 (C), Jurkat (D) and Ramos (E) cell lines (reduced conditions).
11-575 IP
Immunoprecipitation of EGFR from EGF-treated A431 cells by monoclonal antibodies EM-12 (A), EM-13 (B), a commercial anti-EGFR polyclonal antibody (C) and anti-EGFR monoclonal mAb108 (D). The precipitates were immunoblotted with EM-12 or EM-13 antibody, and goat anti-mouse-HRP.
11-575 IP 2
Immunoprecipitation of EGFR from EGF-treated A431 cells by phosphospecific monoclonal antibodies EM-12 (A), EM-13 (B), a commercial anti-EGFR polyclonal antibody (C) and anti-EGFR monoclonal mAb108 (D). The precipitates were immunoblotted with a commercial anti-EGFR polyclonal and goat anti-rabbit-HRP.

General references:

Yan F, Cao H, Chaturvedi R, Krishna U, Hobbs SS, Dempsey PJ, Peek RM Jr, Cover TL, Washington MK, Wilson KT, Polk DB: Epidermal growth factor receptor activation protects gastric epithelial cells from Helicobacter pylori-induced apoptosis. Gastroenterology. 2009 Apr;136(4):1297-1307, e1-3.
PubMed
Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW, Lam WL, Varella-Garcia M, Minna JD, Gazdar AF: Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE. 2009;4(2):e4576.
PubMed
Rappl A, Piontek G, Schlegel J: EGFR-dependent migration of glial cells is mediated by reorganisation of N-cadherin. J Cell Sci. 2008 Dec 15;121(Pt 24):4089-97.
PubMed
Batzer AG, Blaikie P, Nelson K, Schlessinger J, Margolis B: The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor. Mol Cell Biol. 1995 Aug;15(8):4403-9.
PubMed
Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001 Dec 15;61(24):8887-95.
PubMed
Variant
0.1 mg
11-575-C100
In stock

0.025 mg
11-575-C025
In stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock